Numerous studies on treatment for idiopathic pulmonary fibrosis (IPF) focus on inhibiting the TGF-β pathway, including antagonizing TGF-β, inhibiting Smad2/3 phosphorylation, and activating Smad7 [39]. The gene discussed is TGFB1; the disease is pulmonary fibrosis.